The link you have chosen leads to a site maintained by a third party over whom Bracco Imaging has no control. As such, Bracco Imaging makes no representation as to the accuracy or any other aspect of the information on this site. The clinical use of Bracco Imaging Products in these pages may not be consistent with the approved indications.
The information on this site is not country specific and may contain information that is outside the approved indication where you practice.
Please contact your local Bracco Imaging representative for the latest Bracco Imaging product information specific to your country.
SurgVision
In October, 2017 Bracco acquired SurgVision, a high-tech innovative start-up company specialized in developing a real-time Fluorescence Image Guided Surgery platform combining a targeted imaging agent and a device for efficient tumor visualization during oncology surgical procedures.
As surgery remains the primary curative option for most solid cancers, a predominant challenge for surgeons during these procedures has been the limitations of visual inspection and digital palpation to distinguish tumors from healthy tissue. Fluorescence Image Guided Surgery represents an innovative intra-operative optical technique aimed at assisting surgeons in distinguishing tumors from surrounding tissue, using a combined infrared camera and contrast agent approach. In this context, SurgVision’s innovative targeting solution is expected to provide significant improvements versus competing modalities and products, due to the extremely advanced features of its optical camera and the very sensitive targeting performance of its new imaging agent.
It's the company's mission to:
- provide researchers and clinicians with a custom designed optical imaging camera system that allows a smooth transition from clinical research to routine applications
- develop integrated optical imaging platforms, including camera, software and target specific tracer(s), for specific disease areas like breast conserving surgery, peritoneal carcinomatosis and esophageal cancer
SurgVision was founded in August 2013, as a spin-off of the Technical University of Munich and it is headquartered in Groningen, The Netherlands, with a development team in Munich, Germany.
www.surgvision.com
